COPD drug sales will reach more than $13 billion in top seven markets in 2019

Through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6% annual growth in the chronic obstructive pulmonary disease (COPD) drug market, according to a new report from advisory firm Decision Resources.

The Pharmacor 2010 findings from the topic titled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the USA, France, Germany, Italy, Spain, UK and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade.